Nkx3-1 sarna and klf4 sarna and uses thereof
AssigneeThe Regents of the University of California
InventorLong-Cheng Li
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a NKX3-1 gene product in a cell by contacting the cell with a small activating RNA (saRNA) molecule comprising a ribonucleic strand that is complementary to a promoter region sequence of the NKX3-1 gene. The present disclosure also provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a KLF4 gene product in a cell by contacting the cell with a small activating RNA (saRNA) molecule comprising a ribonucleic strand that is complementary to a promoter region sequence of the KLF4 gene.
Claims50
An isolated composition comprising,
- a small activating RNA (saRNA) molecule comprising at least a first ribonucleic acid strand comprising a sequence selected from SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 4, wherein the sequence is complementary to a promoter region sequence of a NKX3-1 gene and is sufficient to activate transcription of the NKX3-1 gene.
A kit comprising,
- a small activating RNA (saRNA) molecule comprising at least a first ribonucleic acid strand comprising a sequence selected from SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 4, wherein the sequence is complementarity to a promoter region sequence of a NKX3-1 gene and is sufficient to activate transcription of the NKX3-1 gene.
A method to increase expression of a gene comprising:
- introducing a small activating RNA (saRNA) molecule into a mammalian cell in an amount sufficient to increase expression of a NKX3-1 gene, wherein the saRNA molecule comprises at least a first ribonucleic acid strand comprising,
- a sequence selected from SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 4,
- wherein the sequence is complementary to a promoter region sequence of the NKX3-1 gene, and
- wherein the introducing results in an increase in expression of the NKX3-1 gene.
A method of reducing proliferation of a cell in a subject having a cellular proliferative disease comprising,
- administering to the subject an effective amount of a small activating RNA (saRNA) molecule, wherein the saRNA molecule comprises at least a first ribonucleic acid strand comprising
- a sequence selected from SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 4,
- wherein the sequence is complementarity to a promoter region sequence of a NKX3-1 gene, and
- wherein the administering provides for an increase in expression of NKX3-1 polypeptide and a decrease in cellular proliferation.
An isolated composition comprising,
- a small activating RNA (saRNA) molecule comprising at least a first ribonucleic acid strand comprising a sequence selected from SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12, wherein the sequence is complementarity to a promoter region sequence of a KLF4 gene and is sufficient to activate transcription of the KLF4 gene.
A kit comprising,
- a small activating RNA (saRNA) molecule comprising at least a first ribonucleic acid strand comprising a sequence selected from SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12, wherein the sequence is complementarity to a promoter region sequence of a KLF4 gene and is sufficient to activate transcription of the KLF4 gene.
A method to increase expression of a gene comprising:
- introducing a small activating RNA (saRNA) molecule into a mammalian cell in an amount sufficient to increase expression of a KLF4 gene, wherein the saRNA molecule comprises at least a first ribonucleic acid strand comprising,
- a sequence selected from SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12,
- wherein the sequence is complementary to a promoter region sequence of the KLF4 gene, and
- wherein the introducing results in an increase in expression of the KLF4 gene.
A method of reducing proliferation of a cell in a subject having a cellular proliferative disease comprising,
- administering to the subject an effective amount of a small activating RNA (saRNA) molecule, wherein the saRNA molecule comprises at least a first ribonucleic acid strand comprising
- a sequence selected from SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12,
- wherein the sequence is complementarity to a promoter region sequence of a KLF4 gene, and
- wherein the administering provides for an increase in expression of KLF4 polypeptide and a decrease in cellular proliferation.
Dependencies are inferred from the claim text.